Tscan Therapeutics, INC Form 4 insider transactions

Director Katina Dorton acquired stock options for 47,500 shares of TScan Therapeutics, Inc.

Director Barbara Klencke acquired stock options for 47,500 shares of TScan Therapeutics, Inc.

Director Gabriela Gruia acquired stock options for 47,500 shares of TScan Therapeutics, Inc.

Director Garry A. Nicholson acquired stock options in TScan Therapeutics, Inc. on June 12, 2024.

Baker Bros. Advisors LP reports the grant of non-qualified stock options to Dr. Stephen R. Biggar, a director of TScan Therapeutics, Inc., on June 12, 2024.

Chrystal Louis, Chief Medical Officer of TScan Therapeutics, acquired 380,000 stock options on May 1, 2024, according to a Form 4 filing with the SEC.

Baker Bros. Advisors and affiliated entities acquired warrants to purchase common stock of TScan Therapeutics through an underwritten offering, as disclosed in a Form 4 filing with the SEC.

Lynx1 Capital Management LP acquired pre-funded warrants for 5,000,000 shares of TScan Therapeutics, Inc., subject to an exercise limitation.